文献速递心外重症与机械循环支持

持续流左心室辅助装置时代心脏移植物排斥反应

Cardiac allograft rejection in the current era of continuous flow left ventricular assist devices.
PubMed 文献 · J Thorac Cardiovasc Surg · 2020-07-22

该回顾性队列研究纳入2006年7月至2019年3月单中心395例心脏移植患者,比较持续流左心室辅助装置(CF-LVAD)桥接与直接移植的移植后排斥反应。

要点

  • CF-LVAD桥接不增加心脏移植后24个月内中重度急性细胞排斥风险。
  • 匹配后CF-LVAD组2R/3R排斥累积发生率数值上低于直接移植组,但差异无统计学意义。

核心结论

  • 校正协变量后,CF-LVAD与心脏移植后24个月内中重度急性细胞排斥风险增加无关。

研究设计与样本

  • 单中心回顾性队列研究,纳入2006年7月至2019年3月395例心脏移植患者,分为直接移植组145例和CF-LVAD组207例,倾向评分匹配13个协变量后每组122例。

关键数值与推荐

  • 2R/3R急性细胞排斥为中度至重度排斥。
  • 倾向评分匹配采用0.1卡尺、最近邻1:1匹配、13个协变量。

临床怎么用

  • CF-LVAD桥接患者移植后中重度急性细胞排斥风险与直接移植者相当,可参考常规排斥监测策略。

局限性

  • 单中心回顾性设计,样本量有限,作者指出需更大队列进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Left ventricular assist device (LVAD) implantation has been shown to increase allosensitization before orthotopic heart transplantation, but the influence of LVAD support on posttransplant rejection is controversial. This study examines the postoperative incidence of acute cellular rejection (ACR) in patients bridged with continuous flow LVAD (CF-LVAD) relative to primary transplant (Primary Tx). METHODS: All patients who underwent orthotopic heart transplantation at our institution between July 2006 and March 2019 were retrospectively reviewed (n = 395). Patients were classified into Primary Tx (n = 145) and CF-LVAD (n = 207) groups. Propensity score matching on 13 covariates implemented a 0.1 caliper logistic model with nearest neighbor 1:1 matching. Development of moderate to severe (ie, 2R/3R) rejection was evaluated using a competing risks model. Potential predictors of 2R/3R ACR were evaluated using Fine-Gray regression on the marginal subdistribution hazard. RESULTS: Propensity score matching yielded 122 patients in each group (n = 244). At 12 and 24 months, the cumulative incidence of 2R/3R ACR was 17% and 23% for the CF-LVAD group and 26% and 31%, respectively, for the Primary Tx group (P = .170). CF-LVAD was not predictive of 2R/3R rejection on multivariable Fine-Gray regression (subdistribution hazard ratio, 0.73; 95% confidence interval, 0.40-1.33; P = .301). There was no difference in the 5-year incidence of antibody mediated rejection (10% [n = 12] vs 9% [n = 11]; P = .827). CONCLUSIONS: After adjusting for covariates, CF-LVAD was not associated with an increased risk of moderate to severe ACR during the 24 months after cardiac transplantation. Further investigation is warranted with larger cohorts, but CF-LVAD may have minimal influence on posttransplant ACR.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Bakir NH, Finnan MJ, MacGregor RM, et al. Cardiac allograft rejection in the current era of continuous flow left ventricular assist devices. J Thorac Cardiovasc Surg. 2020. PMID: 33012541. doi:10.1016/j.jtcvs.2020.06.142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。